Mary Oerline

2.0k total citations · 1 hit paper
56 papers, 1.4k citations indexed

About

Mary Oerline is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Surgery. According to data from OpenAlex, Mary Oerline has authored 56 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 21 papers in Economics and Econometrics and 8 papers in Surgery. Recurrent topics in Mary Oerline's work include Prostate Cancer Diagnosis and Treatment (17 papers), Prostate Cancer Treatment and Research (17 papers) and Healthcare Policy and Management (15 papers). Mary Oerline is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (17 papers), Prostate Cancer Treatment and Research (17 papers) and Healthcare Policy and Management (15 papers). Mary Oerline collaborates with scholars based in United States and United Kingdom. Mary Oerline's co-authors include Justin B. Dimick, Nancy J. O. Birkmeyer, Jonathan F. Finks, Mousumi Banerjee, Arthur M. Carlin, John D. Birkmeyer, Brent K. Hollenbeck, Vahakn B. Shahinian, Lindsey A. Herrel and Megan E.V. Caram and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Mary Oerline

48 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Surgical Skill and Complication Rates after Bariatric Surgery

2013 1.0k citations John D. Birkmeyer, Jonathan F. Finks et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Oerline United States	10	987	434	253	243	227	56	1.4k
Yas Sanaiha United States	21	902 0.9×	568 1.3×	282 1.1×	133 0.5×	398 1.8×	165	1.7k
Azeem Tariq Malik United States	21	1.2k 1.2×	337 0.8×	73 0.3×	170 0.7×	88 0.4×	128	1.6k
Jonah J. Stulberg United States	26	1.5k 1.5×	563 1.3×	99 0.4×	450 1.9×	275 1.2×	72	2.3k
Sameer Hirji United States	24	1.0k 1.0×	1.2k 2.8×	191 0.8×	139 0.6×	485 2.1×	179	2.1k
Alex M. Almoudaris United Kingdom	17	572 0.6×	444 1.0×	83 0.3×	109 0.4×	170 0.7×	32	1.1k
Ella Huszti Canada	17	445 0.5×	527 1.2×	227 0.9×	103 0.4×	277 1.2×	117	1.7k
Amy M. Cizik United States	21	1.1k 1.1×	223 0.5×	127 0.5×	117 0.5×	135 0.6×	61	1.4k
Patrick Ergina Canada	12	507 0.5×	299 0.7×	79 0.3×	148 0.6×	168 0.7×	24	983
Joseph B. Cofer United States	21	1.2k 1.2×	342 0.8×	79 0.3×	381 1.6×	273 1.2×	46	1.8k
P.T. den Hoed Netherlands	22	1.4k 1.4×	211 0.5×	119 0.5×	86 0.4×	448 2.0×	43	1.7k

Countries citing papers authored by Mary Oerline

Since Specialization

Citations

This map shows the geographic impact of Mary Oerline's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Oerline with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Oerline more than expected).

Fields of papers citing papers by Mary Oerline

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Oerline. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Oerline. The network helps show where Mary Oerline may publish in the future.

Co-authorship network of co-authors of Mary Oerline

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Oerline. A scholar is included among the top collaborators of Mary Oerline based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Oerline. Mary Oerline is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hsi, Ryan S., Mary Oerline, Sara L. Best, et al.. (2025). Comparison of Thiazide Versus Alkali for Kidney Stone Recurrence Among Individuals With Hypocitraturia and High Urine pH. Kidney Medicine. 7(12). 101145–101145.

Schaub, Jennifer A., Mary Oerline, Joseph J. Crivelli, et al.. (2025). The Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists on 24-Hour Urine Parameters. Kidney360. 6(5). 835–847.

Kaufman, Samuel R., Mary Oerline, Xiu Liu, et al.. (2025). Physician Payment Incentives and Active Surveillance in Low-Risk Prostate Cancer. JAMA Network Open. 8(1). e2453658–e2453658.

Oerline, Mary, Samuel R. Kaufman, Arnav Srivastava, et al.. (2024). The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer. Urology Practice. 11(6). 931–938.

Oerline, Mary, et al.. (2024). Preventive Pharmacological Therapy and Risk of Recurrent Urinary Stone Disease. Clinical Journal of the American Society of Nephrology. 19(5). 565–572. 4 indexed citations

Srivastava, Arnav, Xiu Liu, Avinash Maganty, et al.. (2024). Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare. Cancer. 131(1). e35633–e35633.

Hollingsworth, John M., Mary Oerline, Ryan S. Hsi, et al.. (2024). Real-World Effectiveness of Preventive Pharmacological Therapy in Patients With Urolithiasis: A Retrospective Cohort Study. American Journal of Kidney Diseases. 84(1). 83–93.e1. 3 indexed citations

Kaufman, Samuel R., Lindsey A. Herrel, Avinash Maganty, et al.. (2023). The immediate effects of private equity acquisition of urology practices on the management of newly diagnosed prostate cancer. Cancer Medicine. 12(24). 22325–22332. 1 indexed citations

Maganty, Avinash, Samuel R. Kaufman, Mary Oerline, et al.. (2023). Value‐based payment models and management of newly diagnosed prostate cancer. Cancer Medicine. 13(1). e6810–e6810. 2 indexed citations

10.

Kaufman, Samuel R., Mary Oerline, Megan E.V. Caram, et al.. (2023). In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer. JNCI Cancer Spectrum. 7(5).

11.

Kaufman, Samuel R., Lindsey A. Herrel, Avinash Maganty, et al.. (2023). Acquisition of Urology Practices by Private Equity Firms and Performance in the Merit-based Incentive Payment System. Urology Practice. 10(6). 597–603.

12.

Mmonu, Nnenaya A., Yongmei Qin, Samuel R. Kaufman, et al.. (2023). Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities. JCO Oncology Practice. 19(5). e763–e772. 2 indexed citations

13.

Kaufman, Samuel R., Lindsey A. Herrel, Mary Oerline, et al.. (2023). Association between urology practice use of multiparametric MRI and genomic testing and treatment of men with newly diagnosed prostate cancer. Urologic Oncology Seminars and Original Investigations. 41(10). 430.e17–430.e23. 1 indexed citations

14.

Kaufman, Samuel R., Mary Oerline, Megan E.V. Caram, et al.. (2023). Health care delivery system contributions to management of newly diagnosed prostate cancer. Cancer Medicine. 12(16). 17346–17355. 4 indexed citations

15.

Maganty, Avinash, Samuel R. Kaufman, Mary Oerline, et al.. (2023). Association Between Urologist Merit-Based Incentive Payment System Performance and Quality of Prostate Cancer Care. Urology Practice. 11(1). 207–214. 2 indexed citations

16.

Kaufman, Samuel R., Lindsey A. Herrel, Avinash Maganty, et al.. (2023). Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer. Cancer. 130(9). 1609–1617. 2 indexed citations

17.

Schwartz, Eric, et al.. (2021). Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy. JCO Oncology Practice. 18(2). e284–e292. 14 indexed citations

18.

Hollenbeck, Brent K., Mary Oerline, Samuel R. Kaufman, et al.. (2020). Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. Urology. 148. 134–140. 2 indexed citations

19.

Caram, Megan E.V., Samuel R. Kaufman, Parth K. Modi, et al.. (2019). Adoption of Abiraterone and Enzalutamide by Urologists. Urology. 131. 176–183. 22 indexed citations

20.

Birkmeyer, John D., Jonathan F. Finks, Mary Oerline, et al.. (2013). Surgical Skill and Complication Rates after Bariatric Surgery. New England Journal of Medicine. 369(15). 1434–1442. 1011 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact